Importance of optimizing duration of adjuvant immune checkpoint inhibitor therapy to treat postoperative hepatocellular carcinoma after conversion therapy: a case report

Patients with hepatocellular carcinoma at high risk of recurrence after hepatic resection or local ablation often undergo adjuvant immunotherapy with immune checkpoint inhibitors for 1 year in randomized controlled trials, but the appropriateness of this duration is controversial, especially given t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian-Rong, Yang, Da-Long, Wang, Jin-Ming, Tian, Wei, Wei, Wei, Luo, Cheng-Piao, Qi, Lu-Nan, Ma, Liang, Zhong, Jian-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641292/
https://www.ncbi.nlm.nih.gov/pubmed/37965538
http://dx.doi.org/10.1093/jscr/rjad610

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641292/
https://www.ncbi.nlm.nih.gov/pubmed/37965538
http://dx.doi.org/10.1093/jscr/rjad610

Ejemplares similares